Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung injury, inflammation and infectious complications in chronic diseases like (CF) Cystic fibrosis or (AB) Bronchial asthma would be highly beneficial. Investigators propose to establish EBC "breathprints" revealing molecular signatures of pulmonary inflammation and specific respiratory bacterial infections of CF patients and AB. Investigators hypothesize that the analysis of EBC can reveal biomarkers specific for severity of the inflammation, and infection caused by opportunistic pathogens such as P. aeruginosa (PA). With these breath-prints, investigators also propose to establish correlations between respiratory microbiota using traditional methods and CF lung disease severity. Together, the studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of AB and monitoring of CF disease activity, treatment efficacy and PA or another opportunistic infections.
Children/adults with moderate or IgE mediated asthma
Children/adults with cystic fibrosis
Healthy control children/adults without lung disorders
None
* Patients with Diagnosis of Cystic Fibrosis * Patients with Diagnosis of Asthma * Healthy Controls
Cohort
Prospective
Collection of breath condensate
Diagnostic testBreath condensate will be collected from the patients involved in study.
Biomarker identification using method of High Resolution Mass Spectrometry processed on Orbitrap Velos Elite machine
Biomarker iidentification in EBC using method of High Resolution Mass Spectrometry in patients with bronchial astma, cystic fibrosis and healthy control.
FEV1 determination in Cystic Fibrosis patients
Spirometry - FEV1 in Cystic Fibrosis patients and its correlation with biomarker results.
FVC determination in Cystic Fibrosis patients
Spirometry - FVC in Cystic Fibrosis patients and its correlation with biomarker results.
Amylase readings in blood serum in Cystic Fibrosis patients
Amylase readings in blood serum in Cystic Fibrosis patients and its correlation with biomarker results.
Inflamatory biomarker identification using method of High Resolution Mass Spectrometry processed on Orbitrap Velos Elite machine
Inflamatory biomarker identification in EBC using method of High Resolution Mass Spectrometry in patients with bronchial astma, cystic fibrosis and healthy control.
Click on the lead sponsor to view all of their trials.
The Institute of Molecular and Translational Medicine, Czech Republic
Lead sponsor
University Hospital Olomouc
Collaborator
